Alladapt Immunotherapeutics

United States
New Lisbon, Wisconsin, United States, 94025

Company profile

Alladapt Immunotherapeutics company profile

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
94025
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$179M
Last funding
Debt Financing / $50M / 2022-08-30
Last equity funding
Series Unknown / $119M
Investors
15
Lead investors
3
Founders
2
Articles
24

Founders and investors

Founders

Ashley DombkowskiKari Nadeau

Lead investors

Gurnet Point CapitalHercules CapitalPatient Square Capital

Investors

Anne WojcickiHercules CapitalNovartisPatient Square CapitalRed Tree Venture Capital